These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1137 related articles for article (PubMed ID: 3474463)
1. Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin. Finlay GJ; Ching LM; Wilson WR; Baguley BC J Natl Cancer Inst; 1987 Aug; 79(2):291-6. PubMed ID: 3474463 [TBL] [Abstract][Full Text] [Related]
2. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells. Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924 [TBL] [Abstract][Full Text] [Related]
3. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells. Jayaram HN; Zhen W; Gharehbaghi K Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964 [TBL] [Abstract][Full Text] [Related]
4. Action of 2-beta-d-Ribofuranosylthiazole-4-carboxamide (tiazofurin) in Chinese hamster ovary and variant cell lines. Saunders PP; Kuttan R; Lai MM; Robins RK Mol Pharmacol; 1983 Mar; 23(2):534-9. PubMed ID: 6188036 [TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin. Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562 [TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752 [TBL] [Abstract][Full Text] [Related]
7. The antitumor effect of Tiazofurin (TR) consists of anti-proliferative and anti-invasive elements. Tóvári J; Bocsi J; Ladányi A; Lapis K; Timár J Anticancer Res; 1996; 16(6A):3307-12. PubMed ID: 9042305 [TBL] [Abstract][Full Text] [Related]
8. Synergistic action of tiazofurin and genistein in human ovarian carcinoma cells. Li W; Weber G Oncol Res; 1998; 10(3):117-22. PubMed ID: 9700722 [TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813 [TBL] [Abstract][Full Text] [Related]
10. Unique bioactivation of tiazofurin--studies with resistant cells. Kuttan R Indian J Biochem Biophys; 1989 Jun; 26(3):160-5. PubMed ID: 2620910 [TBL] [Abstract][Full Text] [Related]
11. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127 [TBL] [Abstract][Full Text] [Related]
12. Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidase. Fridland A; Connelly MC; Robbins TJ Cancer Res; 1986 Feb; 46(2):532-7. PubMed ID: 3000575 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of resistance to tiazofurin in hepatoma 3924A. Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729 [TBL] [Abstract][Full Text] [Related]
14. Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells. Kharbanda SM; Miyazaki K; Takeyama H; Sherman ML; Spriggs DR; Carney WP; Kufe DW Cancer Commun; 1989; 1(3):191-7. PubMed ID: 2639729 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Pani A; Marongiu ME; Pinna E; Scintu F; Perra G; Montis AD; Manfredini S; La Colla P Anticancer Res; 1998; 18(4A):2623-30. PubMed ID: 9703919 [TBL] [Abstract][Full Text] [Related]
16. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208 [TBL] [Abstract][Full Text] [Related]
17. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
18. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of tiazofurin (NSC 286193) in treating disseminated tumor cells and micrometastases in mice. Lapis K; Pápay J; Paku S Oncology; 1990; 47(4):359-64. PubMed ID: 2367062 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug. Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]